Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla®
(apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy